Jan 12 (Reuters) - Akebia Therapeutics Inc AKBA.O:
AKEBIA THERAPEUTICS INC - AKB-097 PHASE 2 RARE KIDNEY DISEASE BASKET TRIAL SCHEDULED TO BEGIN IN 2H 2026 WITH INITIAL DATA EXPECTED IN 2027
Source text: ID:nGNX8XRBb8
Further company coverage: AKBA.O
((Reuters.Briefs@thomsonreuters.com;))